Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 19;72(20):559-563.
doi: 10.15585/mmwr.mm7220a4.

Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022

Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022

Eli S Rosenberg et al. MMWR Morb Mortal Wkly Rep. .

Abstract

In 2022, an international Monkeypox virus outbreak, characterized by transmission primarily through sexual contact among gay, bisexual, and other men who have sex with men (MSM), resulted in 375 monkeypox (mpox) cases in the state of New York outside of New York City (NYC).*, The JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), licensed by the U.S. Food and Drug Administration (FDA) against mpox as a 2-dose series, with doses administered 4 weeks apart,§ was deployed in a national vaccination campaign. Before this outbreak, evidence to support vaccine effectiveness (VE) against mpox was based on human immunologic and animal challenge studies (1-3). New York State Department of Health (NYSDOH) conducted a case-control study to estimate JYNNEOS VE against diagnosed mpox in New York residents outside of NYC, using data from systematic surveillance reporting. A case-patient was defined as a man aged ≥18 years who received a diagnosis of mpox during July 24-October 31, 2022. Contemporaneous control patients were men aged ≥18 years with diagnosed rectal gonorrhea or primary syphilis and a history of male-to-male sexual contact, without mpox. Case-patients and control patients were matched to records in state immunization systems. JYNNEOS VE was estimated as 1 - odds ratio (OR) x 100, and JYNNEOS vaccination status (vaccinated versus unvaccinated) at the time of diagnosis was compared, using conditional logistic regression models that adjusted for week of diagnosis, region, patient age, and patient race and ethnicity. Among 252 eligible mpox case-patients and 255 control patients, the adjusted VE of 1 dose (received ≥14 days earlier) or 2 doses combined was 75.7% (95% CI = 48.5%-88.5%); the VE for 1 dose was 68.1% (95% CI = 24.9%-86.5%) and for 2 doses was 88.5% (95% CI = 44.1%-97.6%). These findings support recommended 2-dose JYNNEOS vaccination consistent with CDC and NYSDOH guidance.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Charles J. Gonzalez reports Ryan White Part B support from the Health Resources and Services Administration, including travel or support for attending meetings and participation on an advisory board for the Center for AIDS Research Supplement for Designing Differentiated PrEP Service Delivery Models for Implementation in New York City Emergency Departments, through the PrEP-ED Community Collaborative. No other potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Reported mpox cases and first and second JYNNEOS vaccine doses administered, by week — New York,* June 2–December 31, 2022 Abbreviation: Mpox = monkeypox. * Outside of New York City.

References

    1. Pittman PR, Hahn M, Lee HS, et al. Phase 3 efficacy trial of Modified Vaccinia Ankara as a vaccine against smallpox. N Engl J Med 2019;381:1897–908. 10.1056/NEJMoa1817307 - DOI - PubMed
    1. Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid Modified Vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine 2015;33:5225–34. 10.1016/j.vaccine.2015.06.075 - DOI - PMC - PubMed
    1. Earl PL, Americo JL, Wyatt LS, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 2008;105:10889–94. 10.1073/pnas.0804985105 - DOI - PMC - PubMed
    1. Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 vaccine effectiveness in New York state. N Engl J Med 2022;386:116–27. 10.1056/NEJMoa2116063 - DOI - PMC - PubMed
    1. Payne AB, Ray LC, Cole MM, et al. Reduced risk for mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons—43 U.S. jurisdictions, July 31–October 1, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1560–4. 10.15585/mmwr.mm7149a5 - DOI - PMC - PubMed

Substances